Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Mechanisms of resistance to anti-cancer drugs, particularly platinum-based agents, remain incompletely understood.
• Epithelial-mesenchymal transition (EMT)-like characteristics in diffuse-type stomach adenocarcinoma contribute to its higher malignancy compared to intestinal-type.
• Identifying novel therapeutic targets is essential for overcoming drug resistance in various cancers.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying resistance to platinum-based anti-cancer drugs.
• To analyze gene expression and molecular networks in different cancer types, including diffuse and intestinal stomach adenocarcinomas.
• To identify upstream regulators and interacting pathways involved in drug resistance, including the tumor microenvironment.

Main Methods:

• Analysis of molecular networks for cisplatin, carboplatin, oxaliplatin, and arsenic trioxide across multiple cancer types.
• Comparative gene expression and molecular network analysis between diffuse and intestinal stomach adenocarcinomas.
• Upstream regulator analysis to identify key factors influencing drug response, including histone deacetylase inhibitors like trichostatin A (TSA).

Main Results:

• Carboplatin analysis identified a causal network in diffuse large B-cell lymphoma.
• Upstream regulators of cisplatin-treated lung adenocarcinoma included TSA, with increased FAS, BTG2, SESN1, and CDKN1A, implicating the tumor microenvironment pathway.
• Oxaliplatin analysis revealed inactivation of the SPINK1 pancreatic cancer pathway in ischemic cardiomyopathy.
• Predicted interactions with microRNAs suggest potential for new drug target identification.

Conclusions:

• Molecular network analysis provides critical insights into anti-cancer drug resistance mechanisms.
• The tumor microenvironment plays a significant role in the efficacy of anti-cancer drug treatments.
• Identifying key molecular players and their interactions can lead to the development of novel therapeutic strategies for drug-resistant cancers.